April 2010
Volume 51, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2010
Elevated Serum Eotaxin Levels and Increased Retinal Expression of Eotaxin in Subjects With Age-Related Macular Degeneration Disease
Author Affiliations & Notes
  • F. Mo
    Schepens Eye Research Institute, Boston, Massachusetts
    Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts
  • A. Proia
    Department of Pathology, Duke University Mecial Center, Durham, North Carolina
  • D. Cyr
    Schepens Eye Research Institute, Boston, Massachusetts
  • W. Johnson
    Department of Physics, Suffolk University, Boston, Massachusetts
  • K. Lashkari
    Schepens Eye Research Institute, Boston, Massachusetts
    Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts
  • Footnotes
    Commercial Relationships  F. Mo, None; A. Proia, None; D. Cyr, None; W. Johnson, None; K. Lashkari, None.
  • Footnotes
    Support  Supported by an unrestricted grant from Novartis Institute for Biomedical Research, MA
Investigative Ophthalmology & Visual Science April 2010, Vol.51, 4942. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      F. Mo, A. Proia, D. Cyr, W. Johnson, K. Lashkari; Elevated Serum Eotaxin Levels and Increased Retinal Expression of Eotaxin in Subjects With Age-Related Macular Degeneration Disease. Invest. Ophthalmol. Vis. Sci. 2010;51(13):4942.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To analyze serum eotaxin levels in subjects with different stages of age related macular degeneration (AMD) and to study the expression of eotaxin in postmortem eyes with AMD.

Methods: : Control subjects and those with the following four phenotypes of AMD were recruited (n= 18-20/group): AREDS stage 1 (early AMD); AREDS stage 3 (intermediate dry AMD); advanced AMD with geographic atrophy (GA); and neovascular AMD (CNV). Sera were analyzed with a Luminex-based Bio-plex system for cytokine expression. Postmortem eyes with AMD and controls were staged and processed for immunohistochemistry.

Results: : Serum eotaxin levels were significantly elevated in all stages of AMD including GA, except for neovascular AMD (P<0.07). In post-mortem eyes with AMD, eotaxin expression was enhanced in retinal pigment epithelial and choroidal endothelial cells in early AMD, GA and CNV, and robustly expressed in neovascular endothelium. Eotaxin accumulated within the layers of basal linear/laminar deposits in all stages of AMD. Eotaxin was also detected in the neurosensory retina, with no discernable difference in staining between control and AMD specimens.

Conclusions: : Eotaxin is constitutively expressed in the neural retina. Elevated serum levels and enhanced expression of eotaxin are closely associated with AMD including GA. The robust expression of eotaxin in the neovascular endothelium, and lack of significantly elevated levels in the sera of subject with CNV suggests that local production of eotaxin by neovascular endothelial cells is an important contributor to neovascular AMD.

Keywords: age-related macular degeneration • cytokines/chemokines • inflammation 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×